Bank of New York Mellon Corp Acquires 20,638 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR)

Bank of New York Mellon Corp boosted its stake in shares of Capricor Therapeutics Inc (NASDAQ:CAPR) by 32.6% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 84,027 shares of the biotechnology company’s stock after buying an additional 20,638 shares during the quarter. Bank of New York Mellon Corp’s holdings in Capricor Therapeutics were worth $1,160,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. New York State Common Retirement Fund grew its position in shares of Capricor Therapeutics by 625.0% during the 4th quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company’s stock valued at $80,000 after acquiring an additional 5,000 shares during the period. SG Americas Securities LLC grew its holdings in Capricor Therapeutics by 74.8% during the fourth quarter. SG Americas Securities LLC now owns 15,317 shares of the biotechnology company’s stock valued at $211,000 after purchasing an additional 6,552 shares during the period. The Manufacturers Life Insurance Company purchased a new stake in Capricor Therapeutics in the third quarter worth $161,000. Sassicaia Capital Advisers LLC bought a new stake in shares of Capricor Therapeutics in the third quarter valued at $192,000. Finally, Rhumbline Advisers raised its stake in shares of Capricor Therapeutics by 44.4% in the fourth quarter. Rhumbline Advisers now owns 46,083 shares of the biotechnology company’s stock valued at $636,000 after buying an additional 14,169 shares during the period. Hedge funds and other institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Stock Up 3.3 %

CAPR stock opened at $13.28 on Tuesday. The stock has a 50-day simple moving average of $14.07 and a two-hundred day simple moving average of $14.76. Capricor Therapeutics Inc has a twelve month low of $3.52 and a twelve month high of $23.40. The firm has a market capitalization of $603.84 million, a PE ratio of -12.53 and a beta of 4.10.

Capricor Therapeutics (NASDAQ:CAPR) last posted its earnings results on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.15. Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. The business had revenue of $11.13 million for the quarter, compared to analyst estimates of $9.87 million. On average, equities research analysts anticipate that Capricor Therapeutics Inc will post -1.21 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently weighed in on CAPR. HC Wainwright reissued a “buy” rating and issued a $77.00 price objective on shares of Capricor Therapeutics in a report on Monday, March 17th. Cantor Fitzgerald reissued an “overweight” rating and issued a $30.00 price target on shares of Capricor Therapeutics in a research report on Thursday, March 20th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $34.50.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.